News Researchers Test Medical Cannabis as Treatment for MS-Linked Neuropathic Pain Researchers Test Medical Cannabis as Treatment for MS-Linked Neuropathic Pain by Joana Fernandes, PhD | February 16, 2017 Share this article: Share article via email Copy article link Canadian researchers are testing mice to see if cannabinoid oil products ā a common medical marijuana treatment ā could help alleviate the neuropathic painĀ thatĀ often afflictsĀ patients with multiple sclerosis (MS). The preclinical study, āIdentifying the molecular mechanisms involved in supressing multiple sclerosis induced neuropathic pain following cannabinoid treatment in an animal model of multiple sclerosis (MS),ā is a joint effortĀ between CanniMed Therapeutics and researchers at Canada’sĀ University of Manitoba. Its results may help to support clinical testing ofĀ cannabinoid oil productsĀ inĀ MS patients with chronic pain. Researchers, operating with an $80,000 CDN (about $61,000) grant from CanniMed,Ā will use a mouse model of MS-associated neuropathic pain to test theĀ analgesic effect of two CanniMed oil products. One is CanniMed 10:10, which has an equal concentration of THC (tetrahydrocannabinol) and CBD (cannabidiol); the other is CanniMed 1:20, which contains onlyĀ CBD. The study aims not only to determine if theĀ drugs improve neuropathic pain in the mouse model,Ā but also to uncover the molecular mechanisms they use toĀ exert their beneficial effect. āThis research endeavor will be the first pre-clinical scientific validation to identifying the direct molecular mechanisms of action of herbal medical cannabis oils and their direct potential impact on neuropathic pain for MS patients,ā team leader Michael Namaka, PhD, said in a news release. āWith CanniMedās ability to supply consistent, quality-controlled and pharmaceutical-grade medical cannabis oils for this trial, we are confident that our outcomes will be standardized and provide us with direction on how cannabis oil will also respond in the patient population,” Namaka added. The study’s preliminary results have shed some light on the way such products work, butĀ final results will likely be publishedĀ later this year. āCanniMed is committed to working with leading physicians and researchers across Canada and around the world in the effort of identifying the potential impact of medical cannabis in supporting symptom management of a number of medical conditions,ā saidĀ Brent Zettl, CanniMedās president and CEO. āResearch endeavors like this one will build upon the expanding library of pre-clinical and clinical research in order to demonstrate to patients, physicians, regulatory groups and governments that medical cannabis is an important therapeutic option.ā Print This Page About the Author Joana Fernandes, PhD Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology. Tags Canada, CBD, mouse model, neuropathic pain, THC
April 19, 2024 News by Lindsey Shapiro, PhD AAN 2024: Long-term data support early Kesimpta start in relapsing MS
April 18, 2024 Columns by Benjamin Hofmeister Learning how to write a ‘SOAP’ note feels different after an MS diagnosis
April 18, 2024 News by Marisa Wexler, MS AAN 2024: Sustained myelin, nerve cell gains with long-term CNM-Au8